diagnosticacitogenetica.listarfish.it
ELISA e LC-MS/MS per i Farmaci Biologici, gli anticorpi antifarmaco e gli autoanticorpi HAHA e HAMA
TNF alpha (Infliximab, Remsima, Golimumab, Adalimumab, Etanercept), EGFR (Cetuximab-Erbitux), VEGF
(Bevacizumab), CD20 (Rituximab), HER2 (Trastuzumab), Vedolizumab (Entyvio), Denosumab (Prolia®), Omalizumab
(Xolair®), Tocilizumab (Actemra®), Nivolumab (Opdivo®) e anti HAHA e anti HAMA.
Li StarFish propone una serie di kit per l'applicazione e il
dosaggio dei nuovi farmaci biologici utilizzati
principalmente nelle patologie reumatologiche, psoriasi, patologie
infiammatorie e gastrointestinali (morbo di Crohn) ed in oncologia.
Inoltre i nostri test permettono di valutare gli anticorpi preesistenti o
indotti dall'utilizzo dei farmaci biologici in terapia che possono influenzarne
la risposta.
LISTA PRODOTTI >>Clicca qui
TNFa e TNFa blocker
Determinazione quantitativa
dei TNF blocker, Anti-TNF blocker (Infliximab, Remsima, Golimumab-Simponi®, Adalimumab-Humira®, EtanerceptEnbrel®), Human TNFa e TNF receptor II
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
REMSIMA:
MAT-TR-REMSv1 SHIKARI Q-REMS Enzyme immunoassay for the quantitative determination of free Infliximab
(Remsima®) in serum and plasma CE/IVD.
MAT-TR-AREMSv2 SHIKARI S-AIR Enzyme immunoassay for the quantitative determination of antibodies to Infliximab
Remsima in serum and plasma CE/IVD.
GOLIMUMAB-SIMPONI:
MAT-TR-GOLv2 SHIKARI Q-GOL Enzyme immunoassay for the quantitative determination of free Golimumab
(Simponi®) in serum and plasmA CE/IVD.
MAT-TR-ATGv1 SHIKARI S-ATG Enzyme immunoassay for the qualitative determination of antibodies to Golimumab in
serum and plasma CE/IVD.
INFLIXIMAB:
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
MAT-TR-Q-INFLIXIv2 SHIKARI Q-INFLIXI Enzyme immunoassay for the quantitative determination of free Infliximab
(Remicade®) in serum and plasma CE/IVD.
MAT-TR-ATIv6 SHIKARI Q-ATI Enzyme immunoassay for the quantitative determination of specific antibodies to
infliximab in human serum and plasma CE/IVD.
DRG-EIA5680 TNFa blocker ADA, TOTAL ANTIBODIES AGAINST INFLIXIMAB (Remicade®)
ADALIMUMAB:
MAT-TR-ADAv1 SHIKARI Q-ADA Enzyme immunoassay for the quantitative determination of free adalimumab
(Humira®) in serum and plasma CE/IVD.
MAT-TR-A-ADAv2 SHIKARI S-ATA Enzyme immunoassay for the quantitative determination of antibodies to
adalimumab in serum and plasma CE/IVD.
DRG-EIA56-- TNFa blocker ADA, TOTAL ANTIBODIES AGAINST ADALIMUMAB (Humira®).
ETANERCEPT:
MAT-TR-ETAv2 SHIKARI Q-ETA Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®)
in serum and plasma.
MAT-TR-AETAv2 SHIKARI S-ATE Enzyme immunoassay for the qualitative determination of antibodies to etanercept in
serum and plasma.
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
EGFR Cetuximab
Determinazione quantitativa di EGFR blocker e degli anti-EGFR blocker (Cetuximab)
EGFR Cetuximab:
MAT-TR-CETv1 SHIKARI Q-CET Enzyme immunoassay for the quantitative determination of free Cetuximab (Erbitux®)
in serum and plasma.
MAT-TR-ACETv1 SHIKARI S-ATC Enzyme immunoassay for the qualitative determination of antibodies to cetuximab in
serum and plasma.
VEGF e VEGF blocker
Determinazione quantitativa dei VEGF blocker e degli anti-VEGF blocker (Bevacizumab).
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
Farmaci che agiscono inibendo l’angiogenesi, ostacolando lo sviluppo
dei vasi sanguigni che irrorano i tumori e determinando un arresto della crescita
e la regressione delle neoplasie.
BEVACIZUMAB:
MAT-TR-BEVAv2 SHIKARI Q-BEVA Enzyme immunoassay for the quantitative determination of Bevacizumab
(Avastin®) in serum and plasma.
MAT-TR-ABEVAv2 SHIKARI S-ATB Enzyme immunoassay for the quantitative determination of antibodies to
Bevacizumab (Avastin®) in serum and plasma.
CD20 e anti-CD20
Determinazione qualitativa di anti-CD20 (Rituximab)
MabThera - rituximab
Il
principio attivo rituximab viene MabThera - rituximab
usato per curare il linfoma non Hodgkin, la leucemia linfocitica cronica e l'artrite reumatoide.
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
RITUXIMAB:
MAT-TR-RTXv2 SHIKARI Q-RITUX Enzyme immunoassay for the quantitative determination of Rituximab® (Rituxan®,
Mabthera®) in serum and plasma CE/IVD
MAT-TR-ARTXv2 SHIKARI S-ATR Enzyme immunoassay for the quantitative determination of antibodies to Rituximab
(Rituxan®, Mabthera®) in serum and plasma
HER2 e anti-HER2
Determinazione quantitativa di HER2 (Trastuzumab).
Il Trastuzumab, nome commerciale Herceptin, è un anticorpo monoclonale umanizzato utilizzato per combattere il
carcinoma mammario avanzato, recidivante o diffuso ad altri organi (carcinoma mammario secondario).
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
TRASTUZUMAB:
MAT-TR-TRASv1 SHIKARI Q-TRAS Enzyme immunoassay for the quantitative determination of Trastuzumab
(Herceptin®, Herclon®).
MAT-TR-ATRASV2 SHIKARI S-ATT Enzyme immunoassay for the qualitative determination of antibodies to
Trastuzumab (Herceptin®, Herclon®) in serum and plasma CE/IVD
VEDOLIZUMAB
Determinazione di VEDOLIZUMAB.
Il VEDOLIZUMAB, nome commerciale Entyvio, è impiegato per il trattamento, negli adulti, del Morbo di Crohn (moderatosevero) e della Colite Ulcerosa.
VEDOLIZUMAB:
IMM-KM9600 Vedolizumab drug level LC-MS/MS Kit for the in vitro determination of free vedolizumab
concentration (e. g. Entyvio®) in EDTA plasma and serum.
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
DENOSUMAB
Denosumab (PROLIA®) è un anticorpo monoclonale IgG2 umanizzato con affinità e specificità per RANKL. Inibisce RANKL
dall'attivare il suo recettore, diminuendo in tal modo il riassorbimento osseo. Denosumab ha un peso molecolare di circa
147 kDa ed è prodotto in cellule geneticamente modificate di mammifero.
DENOSUMAB:
MAT-TR-DENv1 SHIKARI Q-DEN Enzyme immunoassay for the quantitative determination of denosumab (Prolia®) in
serum and plasma CE/IVD.
MAT-TR-ATD SHIKARI S-ATD Enzyme immunoassay for the qualitative determination of antibodies to Denosumab in
serum and plasma CE/IVD.
OMALIZUMAB
Omalizumab (Xolair®) è un anticorpo monoclonale IgG1κ umanizzato da DNA ricombinante che si lega
selettivamente alle immunoglobuline E (IgE) umane. Farmaco a prescrizione, iniettabile, usato per il trattamento in adulti,
bambini sopra i 12 anni di età e anziani con moderata a grave asma persistente i cui sintomi dell'asma non sono
controllati da corticosteroidi per via inalatoria.
OMALIZUMAB:
MAT-TR-OMAv1 SHIKARI Q-OMA Enzyme immunoassay for the quantitative determination of omalizumab (Xolair®) in
serum and plasma CE/IVD.
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
MAT-TR-ATOv1 SHIKARI S-ATO Enzyme immunoassay for the qualitative determination of antibodies to Omalizumab
in serum and plasma CE/IVD
TOCILIZUMAB
Tocilizumab (Actemra®) è un
anticorpo monoclonale umanizzato, è un farmaco immunosoppressore ,
studiato principalmente per il trattamento dell'artrite reumatoide (AR) e
dell'artrite idiopatica giovanile sistemica, una grave forma di artrite
reumatoide dei bambini.
Esso è attivo contro il recettore
dell'interleuchina-6 (IL-6R). L'interleuchina-6 (IL-6) è una citochina
che gioca un ruolo importante nella risposta immunitaria ed è implicata
nella patogenesi di molte malattie, quali le malattie autoimmuni, il
mieloma multiplo e il cancro della prostata.
TOCILIZUMAB:
IG-AB108 Enzyme immunoassay for the specific and quantitative determination of free Tocilizumab (Actemra®) in
human serum and plasma CE/IVD.
IG-BB108 Enzyme immunoassay for the semi-quantitative determination of free antibodies to Tocilizumab (Actemra®) in
human serum and plasma CE/IVD
NIVOLUMAB
Nivolumab (Opdivo®) è un anticorpo monoclonale anti-PD-1 che attiva il
sistema immunitario agendo sulle cellule-T, le
quali intervengono con una risposta immune contro le cellule tumorali.
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
Approvato per il trattamento del tumore del polmone, del tumore del rene e del Linfoma di Hodgkin.
NIVOLUMAB:
MAT-TR-Q-NIVOv1
SHIKARI Q-NIVO Enzyme immunoassay for the quantitative determination of nivolumab
(Opdivo®) in serum and plasma CE/IVD
MAT-TR-ATNv1 SHIKARI S-ATN Enzyme immunoassay for the qualitative determination of antibodies to nivolumab
(Opdivo®) in serum and plasma CE/IVD
HAMA e HAHA
Questi test permettono di rivelare la presenza di auto anticorpi HAMA, HAHA e MAHA che possono influenzare la
diagnosi e il trattamento con farmaci biologici nei pazienti.
EPI-KT806 HAHA (Human Anti-human Antibody) ELISA Kit, CE IVD
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
EPI-KT805 HAMA (Human Anti- Mouse Antibody) ELISA Kit, CE IVD
EPI-KT807 MAHA (Mouse Anti-human Antibody) ELISA Kit
Letteratura:
Lee Y.M. et al, Infliximab ‘‘Top-Down’’ Strategy is Superior to
‘‘Step-Up’’ in Maintaining Long-Term Remission in the Treatment of
Pediatric Crohn Disease (2016)
Karkhi et al. Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis (2015)
Farkas K. et al, Efficacy of the new infliximab biosimilar CT-P13
induction therapy in Crohn’s disease and ulcerative colitis experiences
from a single center (2015)
Malickova K, et al, Serum trough infliximab levels: A comparison of
three different immunoassays for the monitoring of CT-P13 (infliximab)
treatment in patients with inflammatory bowel disease, Biologicals
(2015)
Ayd1n C, Ataolu H., Demonstration of β-1,2 Mannan Structures Expressed
on the Cell Wall of Candida albicans Yeast Form But Not on the Hyphal
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
Form by Using Monoclonal Antibodies(2015)
Gabriela Romero, et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer
by Layer Engineered for the Sustainable Delivery of AntiTNF-α
Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies
Administered to Pregnant Women With Inflammatory Bowel Disease on
Long-term Outcome of Exposed Children
Erdemli Ö., et al, In vitro evaluation of effects of sustained anti-TNF
release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid
arthritis synoviocytes
Pallagi-Kunstár Éva et al., Utility of serum TNF-a, infliximab trough
level, and antibody titers in inflammatory bowel disease (2014)
Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report (2014)
Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease (2013).
Bortlik M et al. Pregnancy and newborn outcome of mothers with
inflammatory bowel diseases exposed to anti-TNF-α therapy during
pregnancy: three-center study, by using Matriks Biotek®, SHIKARI®
Q-INFLIXI and SHIKARI® Q-ADA (infliximab and adalimumab)) ELISA Kits IBD
Clinical and Research Centre, ISCARE, Charles University , Prague ,
Czech Republic
Chio C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by
Reducing Brain TNF-α Contents and by Stimulating Newly Formed
Neurogenesis, Mediators of Inflammation, (2013)
Gutierrez A, et al, Genetic susceptibility to increased bacterial
translocation influences the response to biological therapy in patients
with Crohn’s disease, Gut (2013)
Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin
antibodies (aPS/PT) in infliximab-treated patients with inflammatory
bowel diseases, Autoimmun Highlights (2012)
Seok Lee Y, et al, Efficacy of Early Infliximab Treatment for Pediatric
Crohn’s Disease: A Three-year Follow-up, Pediatric Gastroenterology,
Hepatology & Nutrition (2012)
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in
terms of clinical efficacy during the treatment of psoriasis, Journal
of Dermatology (2012)
Bortlik M, et al, Infliximab trough levels may predict sustained
response to infliximab in patients with Crohn’s disease, Journal of
Crohn’s and Colitis (2012)
Bodini G, et al, Clinical relevance of Adalimumab serum concentration
and Anti-Adalimumab antibodies in patients with Chrohn’s disease during
long-term follow up, Italy (2012)
Molnar T, et al, Importance of trough levels and antibody titers on the
efficacy and safety of Infliximab therapy in inflammatory bowel disease,
Hungary (2012)
Kato S, et al, Elevated Serum IgE Prior to Acute Severe Infusion
Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease
Patient, Crohn’s & Colitis Foundation of America (2011)
Adisen E, et al, Anti-infliximab antibody status and its relation to
clinical response in psoriatic patients: A pilot study, Journal of
Dermatology (2010)
Poster:
Mette Julsgaard, et al, Time since last drug exposure in pregnancy
determines Adalimumab and Infliximab levels in neonates(Era Study)
Szepes Z., et al, Clinical utility of measuring serum TNF alpha level,
anti TNF alpha levels and antibody titers in critical situations in
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
inflammatory bowel disease and in psoriasis,(2014)
Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha
therapy(ERA study):Infliximab and adalimumab cord blood levels correlate
with maternal levels at birth, (2014)
Goldberg R., et al, Predictors of sub-therapeutic infliximab
oradalimumab trough levels and anti-drug antibodies and their influence
on therapeutic decisions,(2014)
Bodini G, et al, Correlation between Adalimumab trough
serum concentration, Anti-Adalimumab antibodies and TNF-Alpha levels
with clinical outcome in patients affected by Crohn’s disease, Italy
(2013)
Duricova D, et al, Predictors of sustained response to infliximab with Crohn’s disease: A single cohort study,
Czech Republic
Lukas M, et al, Anti-infliximab antibodies in routine clinical practice is it worth to assess them?, Czech Republic
Malickova K, et al, Relationship between serum trough infliximab levels,
serum antibodies to infliximab, serum albumin levels and clinical
response to infliximab treatment in patients with inflammatory bowel
diseases, Czech Republic (2011)
Malickova K, et al, Formation of antiphospholipid antibodies and
antibodies to infliximab in anti-TNF-alpha antibody-treated patients
with inflammatory bowel diseases, Czech Republic (2011)
Malickova K, et al, Monitoring patients treated with infliximab: Assessing Anti-Infliximab antibodies, Czech Republic
(2009)
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
diagnosticacitogenetica.listarfish.it
Per ulteriori informazioni CONTATTACI
http://diagnosticacitogenetica.listarfish.it
Realizzata con Joomla!
Generata: 10 June, 2017, 16:56
